Characteristics, treatment strategies, and long-term health outcomes of people with bedaquiline-resistant tuberculosis in Karakalpakstan, Uzbekistan – a retrospective cohort study
Clicks: 3
ID: 321614
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #183 of 214 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 214 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Bedaquiline resistance is increasing globally, threatening effectiveness of short regimens for rifampicin/multi-drug resistant (RR/MDR)-tuberculosis. Limited data exist describing the treatment and long-term outcomes of people with bedaquiline-resistant tuberculosis. Methods We did a retrospective cohort study of patients with bedaquiline-resistant tuberculosis in Karakalpakstan, Uzbekistan, from January 2017 until June 2025. Clinical and laboratory records were reviewed to describe treatment regimens, drug sensitivity profiles, and sputum results. We measured time to sustained sputum culture conversion (SCC), mortality, and the proportion of patients who had tuberculosis-free survival (alive, and had completed treatment or were in care, and had SCC) 18 months after bedaquiline resistance was detected. Results Among 50 patients with bedaquiline-resistant tuberculosis who received treatment, the median age was 41 years (IQR: 27-52), 64% (32/50) were male, 69% (34/49) had fluroquinolone resistance, and 32% (16/50) had not previously received bedaquiline. The median treatment duration was 18.8 months (IQR: 9.0-22.4), with bedaquiline prescribed for 84% for a median 5.6 months (IQR: 2.2-12.9), imipenem for 66% for a median 8.1 months (IQR: 4.5-11.3), and amikacin for 50% for a median 7.9 months (IQR: 4.4-11.1). The median time to SCC was 5.9 months (IQR: 2.1-15.9) and the probabilities of survival to 18 months and five years were 79.7% (95% CI: 69.2-91.8) and 63.4% (95% CI: 48.8-82.4). Of 48 patients who had an assessable 18-month outcome, 60.4% (29/48) had tuberculosis-free survival. Conclusions Management of bedaquiline-resistant tuberculosis in Uzbekistan required prolonged anti-tuberculosis therapy, often with injectables, resulting in delayed culture conversion and poor long-term health outcomes.
| Reference Key |
openalex_W7169777248
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Matthew J Saunders, Ekaterine Garsevanidze, Sholpan Allamuratova, Viktorya Cholakyans, Jaishankar Sharma, Azamat Ismailov, Diana Gomez, Michael L. Rekart, Parvati Nair, S. Moe, Zinaida Tigay, Наргиза Парпиева, Khasan Safaev, Camilo Gómez-Restrepo, Norman Sitali, Jose Luis Alvarez, Animesh A. Sinha |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag405
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.